Mabpharm (HKSE:02181) Change In Inventory : HK$-1.36 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Change In Inventory?

Mabpharm's change in inventory for the quarter that ended in Dec. 2023 was HK$1.31 Mil. It means Mabpharm's inventory declined by HK$1.31 Mil from Jun. 2023 to Dec. 2023 .

Mabpharm's change in inventory for the fiscal year that ended in Dec. 2023 was HK$-1.36 Mil. It means Mabpharm's inventory increased by HK$1.36 Mil from Dec. 2022 to Dec. 2023 .

Mabpharm's Total Inventories for the quarter that ended in Dec. 2023 was HK$111.61 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Mabpharm's Days Inventory for the quarter that ended in Dec. 2023 was 3,271.78.

Inventory Turnover measures how fast the company turns over its inventory within a year. Mabpharm's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.06.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Mabpharm's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 2.38.

Mabpharm Change In Inventory Historical Data

The historical data trend for Mabpharm's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Change In Inventory Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

5.63

-13.31

-24.24

-53.14

-1.36

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Inventory	Get a 7-Day Free Trial								-19.05	-31.82	-22.83	-2.67	1.31

Mabpharm Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.36 Mil.

Mabpharm (HKSE:02181) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Mabpharm's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	112.2625	/	6.262	*	365 / 2
	=	3,271.78

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Mabpharm's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	6.262	/	112.2625
	=	0.06

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Mabpharm's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	112.2625	/	47.187
	=	2.38

Mabpharm Change In Inventory Related Terms

Thank you for viewing the detailed overview of Mabpharm's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines